US EditionPinnacle West: Q2 Earnings Snapshot
UNITED STATES, AUG 6 – BioCryst Pharmaceuticals reported adjusted earnings of $2.29 per share in Q2, surpassing analyst expectations and signaling strong financial performance this quarter.
- On Tuesday, BioCryst Pharmaceuticals reported net income of $6.1 million and adjusted earnings of $2.29 per share.
- Projections from Zacks Investment Research showed analysts expected earnings of 24 cents per share, with results surpassing Wall Street expectations.
- BioCryst Pharmaceuticals, Inc. reported revenue of $1.59 billion, surpassing Street forecasts and exceeding Wall Street expectations.
- Market reaction followed, as BioCryst Pharmaceuticals shares surged over 7% in the last 12 months after results surpassed Wall Street expectations.
- Looking ahead generated by share gains, BioCryst Pharmaceuticals shares have climbed slightly more than 7% in the last 12 months.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
Coverage Details
Total News Sources36
Leaning Left9Leaning Right3Center14Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 35%
C 54%
12%
Factuality
To view factuality data please Upgrade to Premium